Menopause Related Vasomotor Symptoms Market Size, Share, Trend, Scope Report 2026 to 2035

What is Menopause Related Vasomotor Symptoms Market Size?

Menopause Related Vasomotor Symptoms Market Size is valued at USD 12.16 Bn in 2025 and is predicted to reach USD 20.28 Bn by the year 2035 at an 5.4% CAGR during the forecast period for 2026 to 2035.

Menopause Related Vasomotor Symptoms Market Size, Share & Trends Analysis Distribution by Treatment Type (Hormone Therapy, Estrogen-only Therapy, Non-Hormonal Treatment, Neurokinin, SSRIs/SNRIs, Gabapentinoids, Others, Dietary Supplements), by Menopause Stage (Premature Menopause, Perimenopause, Post-menopause), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Channels) and Segment Forecasts, 2026 to 2035

Vasomotor symptoms, particularly hot flashes and night sweats, are among the most common and disruptive symptoms experienced during menopause. Greater awareness of available treatment options, improved diagnosis, and increasing willingness to seek medical support are driving market growth across regions. Hormone therapy is still a key way to manage menopause-related vasomotor symptoms, especially for women who can safely use estrogen-based treatments. The menopause-related vasomotor symptoms market is growing as awareness of menopause and its associated symptoms increases among women, healthcare professionals, and policymakers. As more people talk about menopause and women’s health, the demand for effective treatments is rising. Healthcare providers are also paying closer attention to each patient’s history and risks before recommending hormone therapy. The market is also growing because there are more non-hormonal treatment options available. 

Interest in dietary supplements and wellness products for menopause is rising as more women seek non-pharmaceutical options to manage symptoms. Greater access to health information and a stronger focus on preventive, personalised women’s care are supporting this trend. However, product quality, clinical evidence, appropriate dosing, safety, and regulatory compliance remain essential.

The market is shaped by the different stages of menopause—premature menopause, perimenopause, and post-menopause—each associated with distinct symptom profiles and treatment needs. Perimenopause is particularly significant, as vasomotor symptoms such as hot flashes often begin before the final menstrual period. Earlier recognition of symptoms is prompting women to seek support sooner, encouraging healthcare providers and companies to develop solutions across the full menopause continuum.

Research and product development continue to expand treatment options. Pharmaceutical companies are advancing therapies that improve symptom relief and ease of use, with non-hormonal approaches—especially those targeting the neurokinin pathway—gaining attention as alternatives for women who cannot or prefer not to use hormone therapy. Ongoing clinical research and regulatory approvals are expected to broaden available choices in the coming years.

Despite growth potential, the market faces challenges. Concerns about the safety and suitability of certain hormone-based treatments influence both patient and physician decisions. Individual responses to therapy vary, and some treatments carry side effects or contraindications. Limited awareness in certain populations, uneven healthcare access, treatment costs, and inconsistent diagnosis can also restrict uptake. Strict regulatory requirements for safety, efficacy, quality, labelling, and claims further shape development timelines and costs for both pharmaceutical and supplement products.

Overall, rising menopause awareness, demand for effective symptom management, advances in non-hormonal therapies, and continued pharmaceutical innovation are expected to support market expansion. Greater openness around women’s health and improved access to information create additional opportunities, while stakeholders must continue addressing safety, regulation, affordability, awareness, and healthcare access to sustain growth within women’s health and pharmaceutical care.

Competitive Landscape

Which are the Leading Players in the  Menopause-Related Vasomotor Symptoms Market?

• Cipla
• Teva Pharmaceutical Industries Ltd.
• Pfizer Inc.
• Bayer AG
• Theramex
• Besins Healthcare
• Astellas Pharma Inc.
• Sun Pharmaceutical Industries Ltd.
• Zydus Group
• Hikma Pharmaceuticals Plc.

Driver

Growing Awareness of Menopause and Increasing Demand for Effective Symptom Management is Driving the Menopause-Related Vasomotor Symptoms Market

The global market for menopause-related vasomotor symptoms is growing as more people learn about menopause and how it affects women’s health. Hot flashes and night sweats are common symptoms that can disrupt sleep, daily routines, work, and overall well-being. As more women look for medical help with these symptoms, the need for effective and easy-to-use treatments is rising. Healthcare professionals and organisations are also focusing more on menopause management, helping raise awareness of available treatment options. Hormone therapy remains an important approach for eligible patients, while the development of non-hormonal treatments is creating additional choices for women who cannot or do not want to use hormone-based therapies. Increasing research into the biological causes of vasomotor symptoms is also encouraging pharmaceutical companies to develop more targeted treatment solutions.

The growing focus on women’s health is further supporting market expansion. Menopause is increasingly being discussed as an important healthcare issue rather than a condition that women are expected to manage without medical support. Greater access to health information, telemedicine, digital health platforms, and specialised menopause services is helping women identify symptoms and seek treatment earlier. These factors are expected to support continued demand for therapies used to manage menopause-related vasomotor symptoms.

Restraint/Challenge

Treatment Safety Concerns, Limited Awareness, and High Development Costs Can Limit Market Expansion

The market for menopause-related vasomotor symptoms faces some challenges, such as worries about treatment safety, how people respond differently to treatments, limited awareness, and strict regulations. Hormone therapies can help many women, but whether they are suitable depends on each person’s medical history, age, risk factors, and other health issues. Some patients may be unsure about using hormone therapy because of possible side effects and long-term risks. Non-hormonal therapies offer other options, but not everyone knows about them or can get them, depending on where they live.

Some women may keep using lifestyle changes or manage symptoms on their own because they do not know about medical treatments or cannot reach specialized healthcare services. The pharmaceutical development process is another challenge. New treatments require extensive clinical research, safety evaluation, regulatory approval, and commercialisation investment. These requirements can increase development costs and extend the time needed to bring new therapies to market. In addition, differences in healthcare infrastructure, treatment affordability, reimbursement policies, and access to specialists can affect market adoption. Companies operating in this space therefore need to balance treatment effectiveness, safety, affordability, and patient convenience while meeting regulatory requirements.

Non-Hormonal Treatment Segment is Expected to Witness Strong Growth in the Menopause-Related Vasomotor Symptoms Market

The non-hormonal treatment segment is expected to experience strong growth as more women look for alternatives to hormone therapy. Some women are not suitable candidates for hormone therapy, while others prefer to avoid hormonal treatments because of personal preferences or concerns about potential risks. This is increasing interest in therapies such as SSRIs/SNRIs, gabapentinoids, and newer treatments targeting the neurokinin pathway. The development of targeted non-hormonal therapies is an important factor supporting this segment.

Advances in understanding the neural mechanisms behind hot flashes have created opportunities for pharmaceutical companies to develop treatments designed to reduce vasomotor symptoms. Newer therapies may provide additional options for women who require alternatives to conventional hormone-based approaches. As research continues and more people learn about non-hormonal treatments, doctors will have more options to offer based on each patient’s needs. The trend toward personalized care and better symptom management should help this segment grow in the coming years.

Post-Menopause Segment is Expected to Witness Strong Growth in the Menopause-Related Vasomotor Symptoms Market

The post-menopause segment is expected to account for a significant share of the global Menopause-Related Vasomotor Symptoms Market. Vasomotor symptoms such as hot flashes and night sweats can continue for several years after the final menstrual period, creating a sustained need for symptom management among post-menopausal women. Increasing life expectancy is also contributing to a larger population of women living through the post-menopausal stage. As women remain active in professional, social, and personal activities longer, interest is growing in treatments that can reduce symptoms and improve quality of life. Doctors are paying more attention to personalized menopause care, considering symptom severity, each woman’s medical history, treatment preferences, and overall health. This is increasing demand for both hormonal and non-hormonal treatments. Ongoing awareness campaigns and better access to menopause care should further strengthen the post-menopause segment.

Why North America Led the Menopause-Related Vasomotor Symptoms Market?

North America is expected to remain a leading region in the global Menopause-Related Vasomotor Symptoms Market, supported by high awareness of menopause, advanced healthcare infrastructure, strong pharmaceutical research capabilities, and greater access to treatment options. The U.S. is a major contributor to regional demand, supported by a large post-menopausal population and growing attention to women’s health. The region has a well-established healthcare system with access to gynaecologists, primary-care providers, specialists, hospitals, retail pharmacies, and online healthcare platforms. Women in North America are also increasingly seeking medical advice for menopause symptoms rather than relying only on self-management or lifestyle changes.

Major drug companies and ongoing investment in women’s health research make the regional market even stronger. Companies are working on both hormone-based and non-hormonal treatments, and new approaches that target the causes of vasomotor symptoms are getting more attention. Digital healthcare, telemedicine, online pharmacies, and menopause-focused health platforms are making information and treatment options more accessible. Growing awareness, improved healthcare access, strong pharmaceutical capabilities, and continued product development are expected to keep North America at the forefront of the global menopause-related vasomotor symptoms market.

Key Developments

• In October 2026, Astellas Pharma Inc. presented new real-world data for VEOZAH™ (fezolinetant), showing improvements in bothersome vasomotor symptoms and sleep quality among women with menopause-related hot flashes. The findings further support the role of non-hormonal treatment options for women experiencing moderate to severe vasomotor symptoms.

• In August 2026, Bayer AG received expanded market authorization in Canada for LYNKUET® (elinzanetant) to include moderate to severe vasomotor symptoms caused by adjuvant endocrine therapy related to breast cancer. The development expands the potential use of non-hormonal neurokinin-based treatment for women experiencing hot flashes and night sweats.

Menopause-Related Vasomotor Symptoms Market  Report Scope: